GEMSA  (Synonyms: 2-Guanidinoethylmercaptosuccinic acid)

GEMSA is a potent inhibitor of enkephalin convertase (K_i=8.8 nM). GEMSA elicites analgesia^[1].

Encephalin convertase, K_i 值为8.8 nM.

GEMSA inhibits the activation of TAFI and porcine CBB^[1].
GEMSA can inhibit the prolongation of lysis time in recombinant BAP and does not lead to the lysis of APC fibronectin^[1].
GEMSA inhibits the prolongation of lysis time in porcine CPB, TAFI, and recombinant BAP, APC with the EC₅₀ values of 0.34 μM, 100μM, 115 μM, 90 μM respectively^[1][2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

GEMSA (ICV, 0.1μg/mg, every, 3days) results in a 75% increase in hypothalamic luteinizing hormone-releasing hormone and serum luteinizing hormone levels, and a 60% decrease in serum prolactin concentrations in rat^[3]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

235.26

C₇H₁₃N₃O₄S

77482-44-1

OC(C(SCCNC(N)=N)CC(O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. B Przewlocka, et al. Analgesic and convulsant effects of guanidinoethylmercaptosuccinic acid (GEMSA)--a potent enkephalin convertase inhibitor. Neuropeptides. Nov-Dec 1986;8(4):359-65.  [Content Brief]